What is the main indication for using Selegiline in its patch form?

Selegiline in its patch form is primarily indicated for the treatment of depression, specifically in the context of major depressive disorder. The transdermal delivery of Selegiline provides a continuous release of the medication, allowing for therapeutic levels to be maintained without the gastrointestinal side effects often associated with oral formulations. This method is particularly beneficial in patients who may have difficulty with the traditional oral route or those who prefer not to take multiple pills.

In the transdermal patch form, Selegiline also avoids significant first-pass metabolism in the liver, minimizing the risk of potentially harmful side effects while maximizing its antidepressant effects. This makes it a viable option in the management of depressive disorders, enabling patients to achieve better adherence and consistent symptom relief.